Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DMAC
DIAMEDICA THERAPEUTICS INC.
NASDAQ
$6.75
▲ UP 2.90% (0.19)

KEY STATISTICS

Market Cap$363.71 M
52w High$10.42
52w Low$5.25
Dividend Yield—
Frequency—
P/E-9.51
Volume186.79K
Shares Out.53.88M

COMPANY

LEADERSHIP

Dietrich John Pauls
CHIEF EXECUTIVE
Dietrich John Pauls

COMPENSATION 2026

Salary$645,000
Stock Awards$0
Incentive Plan Pay$412,500
All Other Comp.$17,450
Total$2,727,350

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 3, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
35

PRICE TARGET

Target High$10.00
Target Low$7.00
Target Median$8.00
Target Consensus$8.33

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$13.50M
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2018-11-15Reverse1:20

PRICE

$6.75 ▲ UP 2.90% (+$0.19)
OVERLAYS
$6.60$6.75$6.909:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM6.75

About DiaMedica Therapeutics Inc.

https://www.diamedica.com ↗

DiaMedica Therapeutics Inc. is a clinical-stage biopharma developing treatments for neurological and kidney diseases, with lead candidates DM199 in Phase 2 trials for kidney disease and stroke, and DM300 in pre-clinical stages.

INDUSTRY

Biotechnology

A PRODUCT DIAMEDICA THERAPEUTICS INC. IS KNOWN FOR

DM199 (rinvecalinase alfa)
DM199 (rinvecalinase alfa)

DM199, DiaMedica Therapeutics' lead candidate, is a recombinant KLK1 protein developed to treat ischemic diseases like stroke, preeclampsia, and fetal growth restriction, addressing unmet medical needs with no current approved therapies.

COMPETITORS

COMPETITOR
BIIB COMPARE
MNKD COMPARE
PROK COMPARE
TVTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
33
LISTED HERE
7
RANKED BY POSITION SIZE
IWM
0.01% · 918.8K
VXF
0.00% · 360.6K
R2US.L
0.01% · 45.8K
XRSU.L
0.01% · 33.1K
RSSL
0.01% · 17.4K
URTY
0.00% · 1.4K
RTYS.L
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
22.59%
HOLDERS
129
TOP 12 OF 129 · RANKED BY POSITION SIZE
Cooperman Leon G
3.5M sh · $24.29M
Blackrock, Inc.
2.3M sh · $15.86M
Millennium Management LLC
1.2M sh · $8.16M
Geode Capital Management, LLC
894.1K sh · $6.3M
Paragon Associates & Paragon Associates Ii Joint Venture
875.0K sh · $5.92M
Vanguard Group Inc
723.1K sh · $5.76M
State Street Corp
646.7K sh · $4.55M
Morgan Stanley
579.6K sh · $3.98M
First Manhattan Co. LLC.
505.0K sh · $3.47M
Bleichroeder LP
382.3K sh · $2.69M
Northern Trust Corp
339.6K sh · $2.33M
Advisor Group Holdings, Inc.
338.1K sh · $2.38M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT & CEO
Pauls Dietrich John
Purchase · 60.2K shares
2026-08-10
★
DIRECTOR
Parsons James T.
Purchase · 10.1K shares
2026-01-02
★
DIRECTOR
Giuffre Randall Michael
Purchase · 6.2K shares
2026-01-02
★
DIRECTOR
Semba Charles Pauling
Purchase · 3.4K shares
2026-01-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
DRTS$14.95COMPARE
DSGN$15.28COMPARE
ANNX$4.87COMPARE
ALT$3.38COMPARE
DBVT$13.54COMPARE
GALT$4.63COMPARE
ENGN$1.82COMPARE
KRRO$12.13COMPARE